TargetBeta
FKBP1A
FKBP prolyl isomerase 1A · also FKBP-12, FKBP12, PKC12, PPIASE · FKBP prolyl isomerase family
2 programs in company-led studies act on FKBP1A, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Everolimusrule | Novartis | phase 4 | 1315 running | – | ChEMBL |
| Tacrolimusrule | Astellas Pharma | phase 4 | 1823 running | – | ChEMBL |
Conditions their studies are in
- Arthritis, Rheumatoid, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Carcinoma, Renal Cell, 1 program
- Dermatitis, Atopic, 1 program
- Graft vs Host Disease, 1 program
- Lupus Nephritis, 1 program
- Neuroendocrine Tumors, 1 program
- Renal Insufficiency, 1 program
- Tuberous Sclerosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Tacrolimus · Astellas Pharma · phase 4 · NCT07285070
- Feb 26, 2027Everolimus · Novartis · phase 4 · NCT02962414
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.